Immunome said on Monday its experimental drug met the main goal in a late-stage study for patients with a rare type of tumor, sending its shares up 25% in morning trade.

Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

Valo Health on Thursday announced a strategic partnership worth up to $3B with Germany’s Merck KGaA (OTCPK:MKKGY) to discover medicines for Parkinson’s disease and related disorders, using the ...

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A growing Lexington-based ...

Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson’s Disease and Related Disorders Partnership includes upfront and ...

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in 2014, its patent protection will begin expiring in 2028. This will allow ...

Germany and Taiwan marked a symbolic convergence of politics, culture and industrial strategy on Tuesday evening as the ...